Review article: epoxyeicosatrienoic acids: novel mediators of cardioprotection. J Cardiovasc Pharmacol Ther 2010 Jun;15(2):112-9
Date
03/05/2010Pubmed ID
20200327DOI
10.1177/1074248409358408Scopus ID
2-s2.0-77951884617 (requires institutional sign-in at Scopus site) 43 CitationsAbstract
Recent evidence from a number of in vitro and in vivo studies in isolated cells and animal models has suggested that the cytochrome P450 (CYP450) pathway of arachidonic acid (AA) metabolism produces potent cardioprotective metabolites that markedly reduce reversible (myocardial stunning) and irreversible (infarct size [IS]) injury in the ischemic/reperfused heart. The major players in this protective response appear to be the AA metabolites including the regioisomers of 5,6-, 8,9-, 11,12-, and 14,15-epoxyeicosatrienoic acids (EETs). The present review article will discuss the beneficial effects of the EETs on myocardial stunning and IS reduction and consider some of the signaling pathways and cellular mechanisms by which the EETs produce their beneficial effects and the possible therapeutic benefits that may result from activation of this pathway. The results discussed in this review are taken from experiments obtained from 3 diverse species in different laboratories: the mouse, rat, and dog, in which the results were nearly identical qualitatively and quantitatively, suggesting that these findings are likely to be extrapolated to man as well.
Author List
Nithipatikom K, Gross GJMESH terms used to index this publication - Major topics in bold
AnimalsArachidonic Acid
Arachidonic Acids
Cytochrome P-450 Enzyme System
Mitochondria
Myocardial Infarction
Myocardial Reperfusion Injury
Myocardial Stunning
Natriuretic Peptide, Brain
